FDA Approves Novel Sickle Cell Disease Treatment

December 3, 2019

FDA Approves Novel Sickle Cell Disease Treatment

The FDA granted accelerated approval to Oxbryta (voxelotor), a novel inhibitor of deoxygenated sickle hemoglobin polymerization, the central abnormality in patients with sickle cell disease.The Accelerated Approval pathway enables the FDA to approve drugs for serious conditions based on results showing it is likely to provide clinical benefits to patients. Yourway has extensive experience expediting clinical trials to take advantage of fast-tracked approval pathways.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Global Clinical Supplies Group (GCSG)

October 14-16, 2025
Hungary, Budapest

Schedule a Meeting

Clinical Outsourcing Group (COG)

October 21-22, 2025
Burlingame, California

Schedule a Meeting

Media

Articles

Keeping trials on track: Prioritizing communication in decentralized trials

Open chat

Hello! How can I help you?